IsoRay, Inc. (NYSEMKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has appointed PCG Advisory Group (PCG) as its investor, public and digital communications agency of record.
IsoRay’s CEO Dwight Babcock commented, “We had the opportunity to meet with Jeff Ramson and his team at PCG and we were impressed by their overall knowledge of our business and the competitive landscape we face. In addition, PCG has extensive experience building out digital and social media for their clients. We look forward to working together to refine our digital footprint.”
Jeff Ramson, Founder and CEO of PCG, stated, “IsoRay has unique, cutting edge technology that can fill unmet clinical needs in brain, lung, head and neck, prostate and gynecologic cancers. We look forward to partnering with IsoRay and refining the Company’s messages for investors, the media and social media audiences.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. Cesium-131 is now being used for the treatment of a wide array of cancers throughout the body, including brain, lung, head and neck, chest wall, prostate and gynecologic cancers. (Original Source)
Shares of IsoRay opened today at $1.44 and are currently trading down at $1.43. ISR has a 1-year high of $3.79 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.45 and its 200-day moving average is $1.54.
On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, in a report issued on May 21. The current price target implies an upside of 249.7% from current levels. According to TipRanks.com, Kolbert has a total average return of -9.6%, a 30.9% success rate, and is ranked #3707 out of 3728 analysts.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.